COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Stopped The study was closed due to continued enrollment hurdles.

Conditions

• Rheumatoid Arthritis (RA)
• Systemic Lupus Erythematosus (SLE)
• Pemphigus Vulgaris
• Multiple Sclerosis (MS)
• Systemic Sclerosis (SSc)
• Pediatric SLE
• Juvenile Idiopathic Arthritis (JIA)
• Juvenile Dermatomyositis (JDM)
• Pediatric-Onset Multiple Sclerosis (POMS)

Interventions

• BIOLOGICAL: Moderna mRNA-1273
• BIOLOGICAL: BNT162b2
• BIOLOGICAL: Ad26.COV2.S
• DRUG: Continue IS (MMF or MPA)
• DRUG: Continue IS (MTX)
• BIOLOGICAL: Continue IS (B cell depletion therapy)
• BIOLOGICAL: Monovalent [B.1.351] CoV2 preS dTM-AS03
• DRUG: Withhold IS (MMF or MPA)
• DRUG: Withhold IS (MTX)
• DRUG: Withhold IS (B cell depletion therapy)
• BIOLOGICAL: Moderna mRNA-1273, Bivalent
• BIOLOGICAL: BNT162b2, Bivalent

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

• [object Object]
• [object Object]